title: Prognostic value of nuclear β-catenin overexpression at invasive front in colorectal cancer for synchronous liver metastasis.
abstract: BACKGROUND
  β-catenin plays an important role in colorectal tumorigenesis. Relatively little is known about the relationship between β-catenin overexpression and liver metastasis. The purpose of this study was to investigate whether nuclear β-catenin overexpression in colorectal cancer is associated with synchronous liver metastasis.
  
  
  METHODS
  The β-catenin expression in tumor tissue from 486 patients with colorectal cancer was examined by immunohistochemistry. The relationship between nuclear β-catenin expression in colorectal cancers and liver metastatic lesions and other clinicopathological characteristics was analyzed. Univariate analysis and logistic multivariate regression analysis were adopted to discriminate risk factors of liver metastasis.
  
  
  RESULTS
  Nuclear β-catenin overexpression at the invasive front of the primary tumor in patients with liver metastasis is more evident than that in patients without liver metastasis (71.5% vs. 29.3%; P < 0.001). Nuclear β-catenin expression in primary tumors had a positive correlation with that in the matched metastatic lesions (r = 0.499, P < 0.001). Univariate and multivariate analyses indicated that overexpression of nuclear β-catenin at the invasive front in colorectal cancer correlated with liver metastasis.
  
  
  CONCLUSIONS
  Overexpression of nuclear β-catenin at the invasive front in colorectal cancer is strongly associated with liver metastasis and may be a promising predictor of liver metastasis.
authors.affiliation: Department of General Surgery, Qilu Hospital, Shandong University, Jinan, Shandong, People's Republic of China.
authors.forename: Lin
authors.initials: L
authors.lastname: Wang
authors.forename: Hongxia
authors.initials: H
authors.lastname: Cheng
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.forename: Lei
authors.initials: L
authors.lastname: Wang
authors.forename: Wenbin
authors.initials: W
authors.lastname: Yu
authors.forename: Guangyong
authors.initials: G
authors.lastname: Zhang
authors.forename: Bo
authors.initials: B
authors.lastname: Chen
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Yu
authors.forename: Sanyuan
authors.initials: S
authors.lastname: Hu
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000556:secondary; D002288:Adenocarcinoma, Mucinous / Q000378:metabolism / Q000556:secondary; D000328:Adult; D000368:Aged; D018279:Carcinoma, Signet Ring Cell / Q000378:metabolism / Q000556:secondary; D002467:Cell Nucleus / Q000378:metabolism*; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008113:Liver Neoplasms / Q000378:metabolism* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011379:Prognosis; D016896:Treatment Outcome; D051176:beta Catenin / Q000378:metabolism*
chemical_list: D051176:beta Catenin